Rachna Shroff
Expertise in
11
conditions

Dr. Rachna Shroff

Oncology
Banner Health
University Of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
Banner Health
University Of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I enjoy traveling, dancing and food.

Dr. Shroff is highly rated in 11 conditions, according to our data. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

Her clinical research consists of co-authoring 115 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Thomas Jefferson University Sidney Kimmel Medical College, 2004
Residency
Washington University School of Medicine, Internal Medicine, 2007
Specialties
Oncology
Licenses
Internal Medicine in TX
Board Certifications
American Board Of Internal Medicine/Medical Oncology
Fellowships
University of Texas MD Anderson Cancer Center, Medical Oncology, 2010
Hospital Affiliations
Banner - University Medical Center South
Banner - University Medical Center Tucson
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

University of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, Tucson, AZ 85719
Call: 520-694-2873
Other Locations
Banner-University Medical Center Tucson Campus
1625 North Campbell Avenue, Tucson, AZ 85719
Call: 520-694-0111
University of Arizona Cancer Center
1891 West Orange Grove Road, Building 1, Tucson, AZ 85704
Call: 520-694-2873

Additional Areas of Focus

Dr. Shroff has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Gallbladder Cancer
Anal Cancer
Liver Cancer
Stomach Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Fulvestrant
Study Phase: Phase 2
A Phase 2 Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
A Phase 2 Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: ABC294640, Hydroxychloroquine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 22, 2024
Intervention Type: Drug
Study Drug: HER2/41BB Bispecific
Study Phase: Phase 1
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Phase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Enrollment Status: Unknown
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Other, Biological
Study Drug: Ramucirumab
Study Phase: Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
Immune Response to the COVID-19 Vaccine
Immune Response to the COVID-19 Vaccine
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Biological
Study Drug: SARS-COV2 Pfizer Vaccine
Study Phase: Early Phase 1
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers
A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers
Enrollment Status: Completed
Publish Date: February 02, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

115 Total Publications

ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer.
ACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer.
Journal: Journal of the American College of Radiology : JACR
Published: August 22, 2025
View All 115 Publications
Similar Doctors
Linda Garland
Expertise in
26
conditions
Dr. Linda Garland
Oncology
Expertise in
26
conditions
Dr. Linda Garland
Oncology

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (2.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Garland is an Oncologist in Tucson, Arizona. Dr. Garland is highly rated in 26 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Garland is currently accepting new patients.

Aaron Scott
Expertise in
17
conditions
Dr. Aaron Scott
Oncology
Expertise in
17
conditions
Dr. Aaron Scott
Oncology

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (2.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy advancing medicine through academics and excellent patient care.My particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers. Dr. Scott is highly rated in 17 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Stomach Cancer, and Bone Marrow Aspiration.

Setsuko Chambers
Expertise in
16
conditions
Dr. Setsuko Chambers
Oncology
Expertise in
16
conditions
Dr. Setsuko Chambers
Oncology

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (2.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

My research interests include: CSF-1 and its role in neoplastic progression and metastasis of ovarian cancer; the role of RNA binding proteins and miRNAs in regulation of CSF-1 expression. Androgens and neoplastic transformation of normal ovarian surface epithelium. and the c-fms proto-oncogene and breast cancer invasiveness and bone metastasis; mechanism of regulation of c-fms expression novel c-fms RNA binding proteins and miRNAs. Dr. Chambers is highly rated in 16 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Oophorectomy.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shroff's expertise for a condition
ConditionClose
  • Elite
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Shroff is
    Elite
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Gallbladder Adenocarcinoma
    Dr. Shroff is
    Elite
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Shroff is
    Elite
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Pancreatic Cancer
    Dr. Shroff is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Pancreatic Ductal Adenocarcinoma
    Dr. Shroff is
    Elite
    . Learn about Pancreatic Ductal Adenocarcinoma.
    See more Pancreatic Ductal Adenocarcinoma experts
  • Distinguished
  • Familial Pancreatic Cancer
    Dr. Shroff is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gallbladder Disease
    Dr. Shroff is
    Distinguished
    . Learn about Gallbladder Disease.
    See more Gallbladder Disease experts
  • Advanced
  • Ampullary Cancer
    Dr. Shroff is
    Advanced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Liver Cancer
    Dr. Shroff is
    Advanced
    . Learn about Liver Cancer.
    See more Liver Cancer experts
  • Pancreaticoduodenectomy
    Dr. Shroff is
    Advanced
    . Learn about Pancreaticoduodenectomy.
    See more Pancreaticoduodenectomy experts
  • Pancreatoblastoma
    Dr. Shroff is
    Advanced
    . Learn about Pancreatoblastoma.
    See more Pancreatoblastoma experts
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Shroff is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Bladder Cancer
    Dr. Shroff is
    Experienced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Colorectal Cancer
    Dr. Shroff is
    Experienced
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Familial Colorectal Cancer
    Dr. Shroff is
    Experienced
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Fibrolamellar Carcinoma
    Dr. Shroff is
    Experienced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
  • Lung Cancer
    Dr. Shroff is
    Experienced
    . Learn about Lung Cancer.
    See more Lung Cancer experts
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Oncologists Tucson, AZ
  3. Dr. Rachna Shroff
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.